300750 Contemporary Amperex Technology (A)

DGAP-News: labfolder acquires cubuslab and becomes Labforward

DGAP-News: labfolder GmbH / Key word(s): Mergers & Acquisitions
labfolder acquires cubuslab and becomes Labforward

22.05.2019 / 15:00
The issuer is solely responsible for the content of this announcement.


Lab Notebook learns to communicate with laboratory devices: labfolder acquires cubuslab and becomes Labforward

labfolder GmbH from Berlin and the cubuslab GmbH from Karlsruhe are merging. As a new company called Labforward, they jointly develop a manufacturer-independent platform for the integration of laboratory equipment and laboratory control software. The result is an internationally-operating company with unique expertise in the digital transformation of laboratories.

Berlin / Karlsruhe, 05/22/2019: labfolder GmbH, a leading electronic laboratory notebook (ELN, Electronic Lab Notebook) provider, and cubuslab GmbH, a leading provider of a manufacturer-independent platform for the digital integration of laboratory instruments, today announced their merger. The joint company will operate under the name . Both existing branch offices - Berlin and Karlsruhe - will be retained.

The cubuslab products and the competences of the cubuslab team together with the strengths of labfolder pave the way for an important strategic development. "A laboratory process has three basic steps: planning, execution and documentation," explains Dr. Simon Bungers, CEO and co-founder of labfolder. "With labfolder, we are established in the documentation stage, where all data comes together; with the cubuslab platform and the data from laboratory devices, we simplify and increase the number of data inputs. The cubuslab founders remain in the joint company. Dr. Bungers continues: "We are enormously impressed by what the cubuslab team has achieved. We have known and appreciated each other for several years, so we are looking forward to working together in the future in addition to expanding our expertise."

In contrast to many proprietary solutions, the cubuslab platform can be used to integrate, monitor and control laboratory equipment across different instrument manufacturers. "Labforward therefore also stands for openness and interoperability", says Dr. Dominic Lütjohan, cubuslab CEO and co-founder: "We do not believe that closed systems will be a long-term success on the market. This means that the cubuslab box and software can also talk to other LIMS (Laboratory Information Management Systems) and ELNs and labfolder also interacts with other device platforms. What is important is that we have the expertise in both areas - in the laboratory, where the data is generated, and where the data is stored and processed".

The idea of combining the competencies of both companies was born at the end of 2017: "As alumni of the Merck Accelerator Program, we gave a joint lecture at a conference organized by Merck in Dubai," says Julian Lübke, Head of cubuslab Product and co-founder of cubuslab. "We were already joking after our presentation that we should join forces. In the following year, we worked together on so many projects that the tremendous advantages of the cooperation for both parties became obvious, and the initial joke became a serious opportunity."

cubuslab and labfolder will present the first co-developed innovation at this year's Labvolution in Hannover, Germany: An innovative Lab Execution System (LES) that allows laboratory devices from all manufacturers to be intelligently linked into smart workflows. "This makes laboratory work more efficient and precise," says Dr. Florian Hauer, CPO and co-founder of labfolder. "The automatic data collection and transfer to the labfolder ELN also reduces the documentation effort enormously.

Labforward is currently working with leading companies in Germany, Europe, the USA and Asia to roll out these innovations internationally. The next highlight this autumn is the Beijing Conference and Exhibition on Instrumental Analysis (BCEIA) in Beijing.

Press kit

Link to photos, videos and screenshots:

About labfolder GmbH

labfolder provides a well-designed electronic lab notebook (ELN) for research teams, supporting scientists in their quest to make groundbreaking scientific discoveries. labfolder's software as a service (SaaS) makes it easier to record, retrieve, share, discuss, & validate research data as a team.

labfolder is used by more than 30,000 international scientists in all disciplines. It is used in academia as well as by industrial and pharmaceutical scientists in R&D, analysis, and production labs. To learn more about electronic lab notebooks, please visit:

labfolder was founded in 2013 by molecular biologist Simon Bungers (CEO) and biophysicist Florian Hauer (COO), who were later joined by Yannick Skop (CCO) and Mario Russo (CTO).

The increasing demand of digital solutions for managing growing amounts of scientific data in a regulated environment has resulted in the continuous growth of labfolder, which is supported by investors such as Peppermint Ventures, the IBB Beteiligungsgesellschaft, Vogel Ventures and a consortium of other expert business angels.

Press contact Press contact Web & Social Media Address
Dr. Simon Bungers
Tel.: +49 (0) 30 86459390
mobil: +49 (0) 177 6014270
Susanne Kutter
MC Services AG
Tel.: +49 (0) 211 529252 27
Web:
Blog:
Twitter:
LI:
FB:
labfolder GmbH
Elsenstr. 106
12435 Berlin
Germany
 

About cubuslab GmbH

cubuslab helps scientists in their daily work by connecting, integrating, and automating digital processes, thereby increasing efficiency and creating space for more creativity and curiosity.

With the cubuslab internet-of-things platform, laboratory devices, and equipment, can be remotely controlled and monitored. Data is stored centrally and is always available everywhere. Digital data acquisition avoids errors compared to manual data transfer to a laboratory book or LIMS system and, thanks to automated documentation, experiments can be reproduced without any additional effort.

The cubuslab GmbH was founded in 2015 in Karlsruhe by Dr. Dominic Lütjohann (CEO) and Julian Lübke (Head of Product), and it works with various DAX 30 companies from the pharmaceutical and chemical industry on solutions in the areas of monitoring, asset management, and lab execution.

Press contact Web & Social Media Address
Dr. Dominic Lütjohann
Tel.: +49 (0) 721 75403948
Web:
Twitter:
LI:
Lange Str. 2
76199 Karlsruhe
Germany


22.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


814083  22.05.2019 

fncls.ssp?fn=show_t_gif&application_id=814083&application_name=news&site_id=research_pool
EN
22/05/2019

Underlying

300750Contemporary Amperex Technology (A)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Contemporary Amperex Technology (A)

 PRESS RELEASE

DGAP-News: ADL Bionatur Solutions Wins New Fermentation Client With Co...

DGAP-News: ADL Bionatur Solutions / Key word(s): Agreement ADL Bionatur Solutions Wins New Fermentation Client With Contract Revenues of EUR 20 Million 02.12.2019 / 09:06 The issuer is solely responsible for the content of this announcement. ADL BIONATUR SOLUTIONS WINS NEW FERMENTATION CLIENT WITH CONTRACT REVENUES OF EUR 20 MILLION The agreement with a leading Swiss biotech company includes technology transfer, upscaling and industrial-scale production of high value-added innovative ingredients for the cosmetics and nutrition industry ADL to apply its expertise in a...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: Dozens Savings Plc 5.00% Secured Bonds due 2 December 2020 ISIN: GB00BL1GTZ11  Symbol: DS04 EMS: 1 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   W...

 PRESS RELEASE

Admission of Security to Trading

NEX Exchange (NEXX) Admission of Security to Trading 02-Dec-2019 / 07:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. The following security will be admitted to trading on the NEX Exchange Growth Market with effect from 08:00, 02/12/2019. Name of Issuer: SAPO PLC Ordinary Shares of GBP 0.01 ISIN: GB00B16GQJ90 Symbol: SAPO EMS: 5000 The Regulation Department NEX Exchange London Fruit & Wool Exchange 1 Duval Square London E1 6PW Tel: 020 7858 1655 Email:   Website: ...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publishes open letter to Dr. Martin Haefner...

EQS Group-News: Dynamics Group AG / Key word(s): Statement/Corporate Action LIWET HOLDING AG publishes open letter to Dr. Martin Haefner in various Swiss Sunday newspapers 01.12.2019 / 05:59 Open letter to Dr. Martin Haefner Dear Mr Haefner We share your concern about the future of Schmolz+Bickenbach (S+B). The company urgently needs money, everyone - including Liwet - agrees. However, there is still time to find a constructive solution for S+B that is in the interest of all, not only one particular shareholder. Liwet is ready to rescue the company and the 10,000 jobs. Liw...

 PRESS RELEASE

EQS-News: LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haef...

EQS Group-News: Dynamics Group AG / Schlagwort(e): Stellungnahme/Kapitalmaßnahme LIWET HOLDING AG publiziert offenen Brief an Dr. Martin Haefner in verschiedenen Schweizer Sonntagszeitungen 01.12.2019 / 05:59 Offener Brief an Dr. Martin Haefner Sehr geehrter Herr Haefner Wir teilen Ihre Sorge um die Zukunft von Schmolz+Bickenbach (S+B). Die Firma braucht dringend Geld; damit sind alle - auch Liwet - einverstanden. Noch bleibt Zeit, um eine konstruktive Lösung für S+B zu finden, die im Interesse aller Aktionäre ist, nicht nur eines einzigen. Liwet steht bereit, die Fir...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch